ASCO 2026 showcased how advances in tumor biology, genomic testing, and innovative treatment strategies are reshaping the oncology landscape. This article, from RGA’s ReFlections, examines how the meeting highlighted both the opportunities and ongoing challenges of translating scientific breakthroughs into meaningful improvements in cancer care.
Every year, the world’s leading cancer researchers, clinicians, and industry experts gather in Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting – the premier event on the global oncology calendar.
With more than 40,000 attendees from around the world, ASCO provides a unique opportunity to share the latest advances in cancer prevention, screening, diagnosis, and treatment. The meeting often offers an early glimpse of innovations that may shape future standards of care and influence both clinical practice and research priorities.
This year’s meeting highlighted the rapid evolution of precision oncology, the growing role of genomic testing, the continued expansion of targeted therapies, and the promise – and challenges – of earlier cancer detection.
Together, these developments reinforce how a deeper understanding of tumor biology is translating into more personalized approaches to cancer care.
The following highlights provide a snapshot of some of the most notable studies presented at ASCO 2026. They illustrate both the remarkable progress being made and the significant challenges that remain.
Pancreatic cancer remains one of the most lethal solid organ malignancies, largely because it is often diagnosed at an advanced stage and has limited effective treatment options. Despite advances in oncology, survival outcomes have improved only modestly over recent decades, and metastatic disease continues to carry a particularly poor prognosis. Against this backdrop, the emergence of targeted therapies offers a rare and encouraging development in a disease that has long been associated with significant unmet clinical need.
The headline, “Daily pill can double survival time for world’s deadliest cancer, trial shows,” (The Guardian newspaper)1 highlights a potentially significant advance in the treatment of pancreatic cancer.
Current first-line chemotherapy typically involves the intensive FOLFIRINOX regimen; however, median overall survival remains limited at approximately 11.1 months.2 Once disease progresses, second-line treatment options provide only modest clinical benefits, highlighting the substantial unmet need in this setting.
Approximately 90% of pancreatic cancers harbor a KRAS mutation. KRAS is a molecular on/off switch, critical for regulating cell growth, division, and survival. Daraxonrasib is a novel Ras(On) multi-selective inhibitor designed to switch off KRAS-driven signaling and inhibit tumor growth, regardless of the specific KRAS variant present.
In a 500-patient clinical trial, daraxonrasib increased median overall survival in patients with advanced, previously treated pancreatic cancer from 6.7 months to 13.2 months compared with investigator-selected chemotherapy regimens.
Importantly, the treatment was also associated with a more favorable safety profile. The most common adverse events with daraxonrasib were rash (13.7%) and stomatitis (12.0%), while chemotherapy was more commonly associated with neutropenia (18.2%) and anemia (16.4%).3
The investigators reasonably concluded that, in this historically challenging disease, “daraxonrasib demonstrated unprecedented improvements in overall survival and progression-free survival versus chemotherapy, in patients with pancreatic ductal adenocarcinoma with or without an identified tumor RAS mutation. Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.” These findings support daraxonrasib as a potential new standard of care for previously treated advanced pancreatic cancer. Daraxonrasib (RASONQUE®) received its first regulatory approval from the U.S. FDA in August 2026.
Currently, from an insurance medicine perspective, a diagnosis of metastatic pancreatic cancer is typically considered eligible for terminal illness benefits because of its uniformly poor prognosis. If the survival benefits observed with daraxonrasib are confirmed in broader clinical practice and future studies, pancreatic cancer may eventually join the growing list of metastatic cancers for which advanced-stage disease is no longer synonymous with an immediately terminal prognosis.
A prominent theme emerging from this year’s ASCO Annual Meeting was the continued evolution of precision oncology and the move away from traditional chemotherapy toward targeted therapies designed to exploit specific molecular drivers of cancer.
One example was the growing body of evidence supporting the use of amivantamab, a bispecific antibody targeting both epidermal growth factor receptor (EGFR)-directed and mesenchymal-epithelial transition (MET) receptor pathways. It is currently the first treatment for adults with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations, a subgroup that historically had limited therapeutic options and poor outcomes.
At ASCO, investigators presented results from the OrigAMI-4 study4 evaluating amivantamab in patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who had already progressed despite treatment with both immunotherapy and chemotherapy. This is a particularly challenging clinical setting, as treatment responses are often limited, and survival outcomes remain poor. HPV-positive head and neck cancers generally have a more favorable prognosis than HPV-negative disease. Patients with HPV-unrelated tumors typically experience more aggressive disease and have fewer effective treatment options, once standard therapies have been exhausted. Against this backdrop, the OrigAMI-4 findings3 were particularly encouraging.
Among treated patients, 79% experienced shrinkage of their target lesions with a median duration of response of 7.2 months. Such levels of tumor response are uncommon in a population that has already progressed on multiple lines of therapy. While larger studies will be needed to confirm these results, the findings suggest that dual EGFR/MET inhibition may offer a promising new treatment approach for patients with significant unmet clinical needs.
The study also highlights a broader trend increasingly evident across ASCO presentations: Therapies originally developed for one cancer type are being successfully applied across other tumor types that share similar biological pathways.
This shift reflects the growing emphasis on tumor biology and molecular targets, rather than on tumor location alone, when selecting treatment strategies.
The safety profile of amivantamab was consistent with previous experience in lung cancer and other EGFR/MET-directed therapies. The most common adverse events included hypoalbuminemia, rash, acneiform dermatitis, paronychia, stomatitis, and fatigue.
The OrigAMI-4 results underscore how targeted therapies are continuing to expand beyond their initial indications, offering new hope for patients with advanced cancers that have historically been difficult to treat. They represent another step toward a future where cancer treatment is increasingly driven by molecular characteristics, rather than the organ in which the cancer originated.
Another important theme at ASCO was the continued move toward intensifying treatment earlier in the disease course to improve long-term outcomes. This was exemplified by the PROTEUS trial, which evaluated the addition of apalutamide, an androgen receptor pathway inhibitor, to standard androgen deprivation therapy (ADT) in men with high-risk, locally advanced prostate cancer undergoing radical prostatectomy.
Patients with high-risk disease face a substantial risk of recurrence following surgery, with many ultimately requiring additional treatment and some progressing to metastatic disease, which is associated with significantly poorer outcomes. The PROTEUS study5 enrolled more than 2,100 patients to determine whether adding one year of perioperative apalutamide could improve long-term disease control.
The results were compelling. Fewer patients receiving apalutamide plus ADT required subsequent therapy compared with those receiving ADT alone (42.4% vs. 56.7%).
The combination also substantially prolonged the time to first subsequent treatment (74.2 vs. 41.5 months) and improved event-free survival (57.1 vs. 38.4 months).
Importantly, testosterone recovery following treatment was only modestly delayed, with a median recovery time of 8.1 months compared with 6.6 months in the control arm.
The PROTEUS findings demonstrate the value of earlier, more intensive treatment in high-risk prostate cancer and are expected to establish perioperative apalutamide plus ADT as a new standard of care for patients undergoing surgery for high-risk locally advanced disease.
A theme at ASCO was the increasing use of genomic tools to personalize treatment and identify patients who can safely avoid more intensive therapies without compromising outcomes. In breast cancer, this approach has the potential to reduce treatment-related toxicity while maintaining excellent disease control.
The OPTIMA trial evaluated the use of the Prosigna (PAM50) genomic assay in patients with estrogen receptor-positive (ER+) HER2-negative early breast cancer who would traditionally be considered candidates for chemotherapy.6 The test generates a Risk of Recurrence (ROR) score, helping clinicians identify which patients are most likely to benefit from chemotherapy and which may be adequately treated with endocrine therapy alone.
Patients were randomized to receive standard chemotherapy followed by endocrine therapy or treatment guided by the Prosigna test. Those with higher-risk tumors (ROR >60) received chemotherapy and endocrine therapy, while patients with lower-risk tumors (ROR ≤60) received endocrine therapy alone.
The results demonstrated no meaningful difference in invasive breast cancer-free survival between the treatment groups, indicating that patients with a low Prosigna ROR score can safely forgo chemotherapy without compromising outcomes.
Importantly, this finding extended to groups traditionally viewed as higher risk, including premenopausal women and patients with more extensive nodal involvement.
The OPTIMA findings represent another step toward truly personalized cancer care, enabling more patients to avoid the short- and long-term toxicities of chemotherapy while maintaining excellent outcomes. The study also strengthens the case for broader adoption and routine funding of genomic testing to guide treatment decisions in early breast cancer.
Early cancer detection remains one of the most effective ways to improve cancer outcomes. A key objective of the NHS England Cancer Plan is to increase the proportion of cancers diagnosed at stage I or II from approximately 50% to 75%, and multi-cancer early detection (MCED) blood tests have generated considerable interest as a potential tool to help achieve this goal.
One of the most anticipated studies presented at ASCO was the NHS-Galleri trial, a large randomized controlled study involving more than 142,000 asymptomatic individuals aged 50-79 years. The trial evaluated whether annual screening with the Galleri® MCED blood test, in addition to standard cancer screening programs, could reduce the incidence of advanced cancers by detecting malignancies earlier.7
The results were mixed. The study did not meet its primary endpoint of demonstrating a statistically significant reduction in stage III and IV cancers across 12 pre-specified cancer types.
However, annual MCED testing increased the number of screen-detected cancers approximately fourfold, reduced stage IV cancer diagnoses by 14%, and decreased emergency cancer presentations by 21%.
These findings highlight both the potential and the challenges of MCED screening. Although the primary endpoint was not achieved, the study demonstrated an ability to detect more cancers and shift some diagnoses away from emergency presentations, where outcomes are often poorer. In a separate but related development, on September 23, 2026, the FDA advisory committee voted in favor of approving GRAIL's Galleri® test for premarket approval, an important step in the ongoing evaluation of MCED technology.
The NHS-Galleri study suggests that MCED testing is not yet the transformative population screening solution many had hoped for, but neither is it a failure. Despite ongoing questions regarding sensitivity, cost-effectiveness, implementation, and long-term impact on cancer mortality, increased detection of cancer and reductions in late-stage cancer diagnoses, together with the FDA advisory committee's recommendation to approve Galleri®, suggest that MCED technology may still play an important role as a supplement in cancer screening strategies. FDA approval would be a significant milestone that could accelerate adoption and generate further evidence on the technology's clinical utility. For insurers, MCED testing may warrant continued monitoring as evidence emerges regarding its potential impact on cancer detection, outcomes, and risk assessment.
The remarkable expansion of GLP-1 receptor agonists continues to be one of the most intriguing stories in medicine. Initially developed for diabetes management and now widely used for obesity treatment, these agents have already demonstrated substantial benefits in cardiovascular disease. Emerging evidence presented at ASCO suggests their impact may extend even further.
In a large matched-cohort study, patients with a history of early-stage cancer who were exposed to GLP-1 receptor agonists were less likely to progress to stage IV metastatic disease across six of seven cancer types evaluated.8 Significant benefits were observed in lung, breast, colorectal, and liver cancers. Investigators also reported that higher tumor expression of GLP-1 receptors was associated with improved survival across multiple tumor types, with particularly notable findings in breast cancer.
These findings remain observational and do not establish a causal relationship. However, the consistency of the signal across several cancers has generated considerable interest.
As noted by ASCO presenters, the known anti-inflammatory and immune-modulating effects of GLP-1 therapies provide a biologically plausible explanation and warrant further investigation in prospective randomized trials.
While far from practice-changing, these findings add to the growing list of potential benefits associated with GLP-1 therapies and raise the intriguing possibility that these agents may one day play a role in cancer prevention or progression, in addition to their established metabolic and cardiovascular effects.
ASCO 2026 showcased both the complexity of cancer and the extraordinary progress being made in understanding and treating the disease. From novel, targeted therapies to advances in screening and treatment individualization, the common theme was a move toward more precise, effective, and patient-centered care. However, as the incidence of cancer continues to rise globally, prevention remains the greatest opportunity to reduce the burden of disease. The World Health Organization estimates that up to 40%9 of cancers could be prevented, underscoring the continuing importance of public health initiatives alongside therapeutic innovation.
RGA experts are eager to engage with clients to better understand and tackle the industry’s most pressing challenges together. Contact us to learn more about RGA's capabilities, resources, and solutions.
